Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of AgeMirna Chehade, Jennifer Maloney, Ikuo Hirano et al.|New England Journal of Medicine|2024Cited by 107
Dupilumab Improves Histologic And Endoscopic Outcomes In Children Aged 1 To <12 Years With Eosinophilic Esophagitis (EoE): 52-Week Results From The Phase 3 EoE KIDS TrialMirna Chehade, Arsalan Shabbir, Evan S. Dellon et al.|Journal of Allergy and Clinical Immunology|2024Cited by 7
A Phase 2/3 Study To Assess The Efficacy And Safety Of Dupilumab Versus Placebo In Adults And Adolescents With Eosinophilic Gastritis With Or Without Eosinophilic DuodenitisEvan S. Dellon, Arsalan Shabbir, Marc E. Rothenberg et al.|Journal of Allergy and Clinical Immunology|2024Cited by 1